Tags

Type your tag names separated by a space and hit enter

Purslane suppresses osteoclast differentiation and bone resorbing activity via inhibition of Akt/GSK3β-c-Fos-NFATc1 signaling in vitro and prevents lipopolysaccharide-induced bone loss in vivo.
Biol Pharm Bull. 2015; 38(1):66-74.BP

Abstract

Purslane (Portulaca oleracea L.) is popular as a potherb in many areas of Europe, Asia, and the Mediterranean region and is widely distributed around the globe. It has a wide range of pharmacological effects, such as antibacterial, anti-aging, anti-inflammatory, and anti-oxidative properties. Although the extract of purslane has numerous beneficial pharmacological effects, its effect on osteoclasts remains unknown. We aimed to investigate the anti-osteoclastogenic activity in vitro and in vivo and to elucidate the underlying mechanism. The effect of purslane on the differentiation and function of bone marrow-derived macrophages (BMMs) into osteoclasts was examined using a phenotype assay such as tartrate-resistant acid phosphatase (TRAP) staining, F-actin staining, and pit assay and followed by confirmation by real-time reverse transcription polymerase chain reaction (RT-PCR) and Western blot analysis. To address the effect of purslane in vivo, the inflammatory, lipopolysaccharide (LPS)-induced osteolysis mouse model was chosen. Bone volume and bone microarchitecture were evaluated by microcomputed tomography and histologic analysis. Purslane inhibited receptor activator of nuclear factor-kappa B ligand (RANKL)-stimulated osteoclast differentiation accompanied by inhibition of Akt/glycogen synthase kinase 3β (GSK3β) signaling, which could underlie purslane-induced downregulation of c-Fos and nuclear factor of activated T cells 1 (NFATc1) expression levels, transcription factors that regulate osteoclast-specific genes, as well as osteoclast fusion and resorption-related molecules. Moreover, in vivo studies further verified the bone protection activity of purslane in the LPS-induced osteolysis animal model. Purslane could exhibit its anti-osteoclastogenic activity by inhibiting Akt/GSK3β-c-Fos-NFATc1 signaling cascades. Therefore, purslane is a potential natural medicine for the treatment of osteoclast-related diseases.

Authors+Show Affiliations

Imaging Science-Based Lung and Bone Diseases Research Center, Wonkwang University.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

25744460

Citation

Kim, Ju-Young, et al. "Purslane Suppresses Osteoclast Differentiation and Bone Resorbing Activity Via Inhibition of Akt/GSK3β-c-Fos-NFATc1 Signaling in Vitro and Prevents Lipopolysaccharide-induced Bone Loss in Vivo." Biological & Pharmaceutical Bulletin, vol. 38, no. 1, 2015, pp. 66-74.
Kim JY, Oh HM, Kwak SC, et al. Purslane suppresses osteoclast differentiation and bone resorbing activity via inhibition of Akt/GSK3β-c-Fos-NFATc1 signaling in vitro and prevents lipopolysaccharide-induced bone loss in vivo. Biol Pharm Bull. 2015;38(1):66-74.
Kim, J. Y., Oh, H. M., Kwak, S. C., Cheon, Y. H., Lee, M. S., Rho, M. C., & Oh, J. (2015). Purslane suppresses osteoclast differentiation and bone resorbing activity via inhibition of Akt/GSK3β-c-Fos-NFATc1 signaling in vitro and prevents lipopolysaccharide-induced bone loss in vivo. Biological & Pharmaceutical Bulletin, 38(1), 66-74. https://doi.org/10.1248/bpb.b14-00567
Kim JY, et al. Purslane Suppresses Osteoclast Differentiation and Bone Resorbing Activity Via Inhibition of Akt/GSK3β-c-Fos-NFATc1 Signaling in Vitro and Prevents Lipopolysaccharide-induced Bone Loss in Vivo. Biol Pharm Bull. 2015;38(1):66-74. PubMed PMID: 25744460.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Purslane suppresses osteoclast differentiation and bone resorbing activity via inhibition of Akt/GSK3β-c-Fos-NFATc1 signaling in vitro and prevents lipopolysaccharide-induced bone loss in vivo. AU - Kim,Ju-Young, AU - Oh,Hyun Mee, AU - Kwak,Sung Chul, AU - Cheon,Yoon-Hee, AU - Lee,Myeung Su, AU - Rho,Mun Chual, AU - Oh,Jaemin, PY - 2015/3/7/entrez PY - 2015/3/7/pubmed PY - 2015/12/17/medline SP - 66 EP - 74 JF - Biological & pharmaceutical bulletin JO - Biol Pharm Bull VL - 38 IS - 1 N2 - Purslane (Portulaca oleracea L.) is popular as a potherb in many areas of Europe, Asia, and the Mediterranean region and is widely distributed around the globe. It has a wide range of pharmacological effects, such as antibacterial, anti-aging, anti-inflammatory, and anti-oxidative properties. Although the extract of purslane has numerous beneficial pharmacological effects, its effect on osteoclasts remains unknown. We aimed to investigate the anti-osteoclastogenic activity in vitro and in vivo and to elucidate the underlying mechanism. The effect of purslane on the differentiation and function of bone marrow-derived macrophages (BMMs) into osteoclasts was examined using a phenotype assay such as tartrate-resistant acid phosphatase (TRAP) staining, F-actin staining, and pit assay and followed by confirmation by real-time reverse transcription polymerase chain reaction (RT-PCR) and Western blot analysis. To address the effect of purslane in vivo, the inflammatory, lipopolysaccharide (LPS)-induced osteolysis mouse model was chosen. Bone volume and bone microarchitecture were evaluated by microcomputed tomography and histologic analysis. Purslane inhibited receptor activator of nuclear factor-kappa B ligand (RANKL)-stimulated osteoclast differentiation accompanied by inhibition of Akt/glycogen synthase kinase 3β (GSK3β) signaling, which could underlie purslane-induced downregulation of c-Fos and nuclear factor of activated T cells 1 (NFATc1) expression levels, transcription factors that regulate osteoclast-specific genes, as well as osteoclast fusion and resorption-related molecules. Moreover, in vivo studies further verified the bone protection activity of purslane in the LPS-induced osteolysis animal model. Purslane could exhibit its anti-osteoclastogenic activity by inhibiting Akt/GSK3β-c-Fos-NFATc1 signaling cascades. Therefore, purslane is a potential natural medicine for the treatment of osteoclast-related diseases. SN - 1347-5215 UR - https://www.unboundmedicine.com/medline/citation/25744460/Purslane_suppresses_osteoclast_differentiation_and_bone_resorbing_activity_via_inhibition_of_Akt/GSK3β_c_Fos_NFATc1_signaling_in_vitro_and_prevents_lipopolysaccharide_induced_bone_loss_in_vivo_ L2 - https://dx.doi.org/10.1248/bpb.b14-00567 DB - PRIME DP - Unbound Medicine ER -